Showing 1 - 10 of 13
Pharmaceutical innovation policy involves managing a tradeoff between high prices for new products in the short-term and stronger incentives to develop products for the future. Prior research has documented a causal relationship between market size and pharmaceutical research and development...
Persistent link: https://www.econbiz.de/10012533304
Persistent link: https://www.econbiz.de/10012009103
Persistent link: https://www.econbiz.de/10011708133
Persistent link: https://www.econbiz.de/10010380923
Innovation policy involves trading off monopoly output and pricing today in exchange for incentives for firms to develop new products. While existing research demonstrates that expected profits fuel R&D investments, little is known about the novelty of funded projects. We expand this literature...
Persistent link: https://www.econbiz.de/10012838413
Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for firms to develop new products in the future. While existing research demonstrates that expected profits fuel R&D investments, little is known about the novelty of the projects...
Persistent link: https://www.econbiz.de/10012481677
Prior research has shown that exogenous shocks to the demand for medical products spur additional product development. These studies do not distinguish between breakthrough products and those that largely duplicate the performance of existing products. In this paper, we use a novel data set to...
Persistent link: https://www.econbiz.de/10012458453
Persistent link: https://www.econbiz.de/10012237220
Persistent link: https://www.econbiz.de/10012881699
Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for firms to develop new products in the future. While existing research demonstrates that expected profits fuel R&D investments, little is known about the novelty of the projects...
Persistent link: https://www.econbiz.de/10013309194